PT4268843T - Anticorpos contra il-6 melhorados - Google Patents

Anticorpos contra il-6 melhorados

Info

Publication number
PT4268843T
PT4268843T PT231893850T PT23189385T PT4268843T PT 4268843 T PT4268843 T PT 4268843T PT 231893850 T PT231893850 T PT 231893850T PT 23189385 T PT23189385 T PT 23189385T PT 4268843 T PT4268843 T PT 4268843T
Authority
PT
Portugal
Prior art keywords
antibodies
improved
Prior art date
Application number
PT231893850T
Other languages
English (en)
Portuguese (pt)
Original Assignee
F Hoffmann La Roche Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche Ltd filed Critical F Hoffmann La Roche Ltd
Publication of PT4268843T publication Critical patent/PT4268843T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT231893850T 2014-11-07 2015-11-06 Anticorpos contra il-6 melhorados PT4268843T (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462077105P 2014-11-07 2014-11-07
US201462087448P 2014-12-04 2014-12-04
US201562247705P 2015-10-28 2015-10-28

Publications (1)

Publication Number Publication Date
PT4268843T true PT4268843T (pt) 2025-10-31

Family

ID=54602042

Family Applications (2)

Application Number Title Priority Date Filing Date
PT231893850T PT4268843T (pt) 2014-11-07 2015-11-06 Anticorpos contra il-6 melhorados
PT157975384T PT3215530T (pt) 2014-11-07 2015-11-06 Anticorpos de il-6 melhorados

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT157975384T PT3215530T (pt) 2014-11-07 2015-11-06 Anticorpos de il-6 melhorados

Country Status (32)

Country Link
US (3) US11142571B2 (enExample)
EP (3) EP3632931A1 (enExample)
JP (1) JP6594438B2 (enExample)
KR (2) KR102636726B1 (enExample)
CN (1) CN107249631B (enExample)
AU (1) AU2015342882B2 (enExample)
CA (1) CA2965689C (enExample)
CL (1) CL2017001135A1 (enExample)
CO (1) CO2017005404A2 (enExample)
CR (1) CR20170231A (enExample)
DK (2) DK4268843T3 (enExample)
EA (1) EA035199B1 (enExample)
ES (1) ES2756275T3 (enExample)
FI (1) FI4268843T3 (enExample)
HR (2) HRP20251312T1 (enExample)
HU (1) HUE046181T2 (enExample)
IL (1) IL251858B (enExample)
LT (1) LT4268843T (enExample)
MA (1) MA51554A (enExample)
MX (2) MX385206B (enExample)
MY (1) MY185114A (enExample)
PE (1) PE20171107A1 (enExample)
PH (1) PH12017500809B1 (enExample)
PL (1) PL3215530T3 (enExample)
PT (2) PT4268843T (enExample)
RS (2) RS59805B1 (enExample)
SA (1) SA517381458B1 (enExample)
SG (2) SG10202103420PA (enExample)
SI (1) SI3215530T1 (enExample)
UA (1) UA122673C2 (enExample)
WO (1) WO2016073890A1 (enExample)
ZA (1) ZA201702985B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017053807A2 (en) 2015-09-23 2017-03-30 Genentech, Inc. Optimized variants of anti-vegf antibodies
CN108718522A (zh) * 2016-02-23 2018-10-30 赛森生物股份有限公司 Il-6拮抗剂制剂及其用途
AU2017384528A1 (en) * 2016-12-19 2019-07-04 Ichnos Sciences SA Novel TNFR agonists and uses thereof
EP3600442A1 (en) 2017-03-22 2020-02-05 Genentech, Inc. Optimized antibody compositions for treatment of ocular disorders
EP3600441A1 (en) 2017-03-22 2020-02-05 Genentech, Inc. Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
CN109867723B (zh) * 2017-12-05 2022-06-17 南京金斯瑞生物科技有限公司 抗人il6单克隆抗体及其制备方法和用途
TW202144410A (zh) 2020-03-13 2021-12-01 美商建南德克公司 抗介白素－３３抗體及其用途
JP7720317B2 (ja) 2020-03-24 2025-08-07 ジェネンテック， インコーポレイテッド Ｔｉｅ２結合剤および使用方法
TW202228790A (zh) 2020-10-15 2022-08-01 美商建南德克公司 用於長效經眼遞送之非共價蛋白質－玻尿酸結合物
CN116355825A (zh) * 2022-02-25 2023-06-30 南京工业大学 一种强化纤维素合成来提高人表皮生长因子分泌生产效率的方法
CN115343483B (zh) * 2022-08-12 2024-11-26 苏州邦器生物技术有限公司 一种自身免疫性糖尿病检测用试剂盒及其制备方法
TW202426494A (zh) * 2022-10-24 2024-07-01 瑞士商赫孚孟拉羅股份公司 預測對ｉｌ－６拮抗劑的反應

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4548990A (en) 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
EP1279731B1 (en) 1991-03-01 2007-05-30 Dyax Corporation Process for the development of binding mini-proteins
DE69233367T2 (de) 1991-04-10 2005-05-25 The Scripps Research Institute, La Jolla Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
CA2119930C (en) 1991-09-23 2002-10-01 Hendricus R. J. M. Hoogenboom Production of chimeric antibodies - a combinatorial approach
DK0617706T3 (da) 1991-11-25 2001-11-12 Enzon Inc Multivalente antigenbindende proteiner
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
CA2150262C (en) 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Multivalent and multispecific binding proteins, their manufacture and use
EP0754225A4 (en) 1993-04-26 2001-01-31 Genpharm Int HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
FR2734739B1 (fr) 1995-06-01 1997-07-11 Gec Alsthom Stein Ind Dispositif de surveillance d'un broyeur a boulets
TW311927B (enExample) 1995-07-11 1997-08-01 Minnesota Mining & Mfg
EP0795743A3 (en) 1996-03-15 1998-02-25 Japan Tobacco Inc. Method and apparatus for infra-red moisture measurement
US5839430A (en) 1996-04-26 1998-11-24 Cama; Joseph Combination inhaler and peak flow rate meter
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
ES2246069T3 (es) 1997-05-02 2006-02-01 Genentech, Inc. Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
US6358058B1 (en) 1998-01-30 2002-03-19 1263152 Ontario Inc. Aerosol dispensing inhaler training device
ATE439592T1 (de) 1998-12-10 2009-08-15 Bristol Myers Squibb Co Proteingerüste für antikörper-nachahmer und andere bindende proteine
CA2589418A1 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
ATE378403T1 (de) 2000-11-30 2007-11-15 Medarex Inc Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
AU2002256371B2 (en) 2001-04-26 2008-01-10 Amgen Mountain View Inc. Combinatorial libraries of monomer domains
ATE556591T1 (de) 2001-11-08 2012-05-15 Abbott Biotherapeutics Corp Stabile pharmazeutische flüssigformulierung von igg-antikörpern
BR0309844A (pt) 2002-05-07 2005-02-15 Control Delivery Sys Inc Processos para formação de um dispositivo para a distribuição de droga
CA2506230A1 (en) * 2002-11-15 2004-06-03 Centocor, Inc. Anti-angiogenic uses of il-6 antagonists
BRPI0417270A (pt) 2003-12-23 2007-03-27 Rinat Neuroscience Corp anticorpos agonistas antitrkc e métodos para utilização dos mesmos
EP1776384B1 (en) 2004-08-04 2013-06-05 Mentrik Biotech, LLC Variant fc regions
AU2005282700A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
PT1966244E (pt) 2005-12-30 2012-05-17 Merck Patent Gmbh Anticorpos anti-il-6 impedindo a ligação da il-6 complexada com il-6ralfa a gp130
EP2004690A2 (en) 2006-03-13 2008-12-24 Ablynx N.V. Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
CN101600793B (zh) 2006-05-19 2013-06-26 奥尔德生物制药公司 用于获得抗原特异性b细胞的克隆群体的培养方法
PL3187506T3 (pl) * 2007-05-21 2019-09-30 Alderbio Holdings Llc Przeciwciała przeciwko IL-6 i ich zastosowanie
CN106039299A (zh) 2007-09-14 2016-10-26 赛诺菲巴斯德生物制剂有限责任公司 含艰难梭菌类毒素a和b的药物组合物
KR20100099193A (ko) 2007-11-21 2010-09-10 암젠 인크 Ｗｉｓｅ 결합 항체 및 에피토프
US20100187601A1 (en) 2007-12-12 2010-07-29 Fujio Masuoka Semiconductor device
CA2711984A1 (en) 2008-01-15 2009-07-23 Abbott Gmbh & Co. Kg Powdered protein compositions and methods of making same
EP2328616B1 (en) 2008-08-05 2015-04-29 Novartis AG Compositions and methods for antibodies against complement protein c5
ES2395231T3 (es) 2008-09-12 2013-02-11 Kdf Co., Ltd. Dispositivo de proyección de agua en forma de surtidor
WO2010039750A2 (en) 2008-10-01 2010-04-08 Monsanto Technology Llc Transgenic plants with enhanced agronomic traits
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
EP2356147A1 (en) 2008-11-26 2011-08-17 Glaxo Group Limited Polypeptides, antibody variable domains&antagonists
SG2014007637A (en) 2009-01-29 2014-03-28 Medimmune Llc Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
SG186451A1 (en) 2010-07-12 2013-01-30 Covx Technologies Ireland Ltd Multifunctional antibody conjugates
AU2013288641B2 (en) 2012-07-13 2017-07-06 Roche Glycart Ag Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
SG11201502659YA (en) 2012-10-25 2015-05-28 Medimmune Llc Stable, low viscosity antibody formulation
WO2014074905A1 (en) 2012-11-08 2014-05-15 Eleven Biotherapeutics, Inc. Il-6 antagonists and uses thereof
SG10201912985RA (en) 2013-07-12 2020-02-27 Ophthotech Corp Methods for treating or preventing ophthalmological conditions
WO2016073894A1 (en) 2014-11-07 2016-05-12 Eleven Biotherapeutics, Inc. Therapeutic agents with increased ocular retention

Also Published As

Publication number Publication date
US11142571B2 (en) 2021-10-12
SI3215530T1 (sl) 2020-02-28
MA51554A (fr) 2020-11-18
US20250059270A1 (en) 2025-02-20
HRP20191945T1 (hr) 2020-01-24
KR102770849B1 (ko) 2025-02-20
EA035199B1 (ru) 2020-05-14
PE20171107A1 (es) 2017-08-07
CO2017005404A2 (es) 2017-10-31
PH12017500809A1 (en) 2017-10-02
AU2015342882B2 (en) 2021-05-20
EP3632931A1 (en) 2020-04-08
KR20170077196A (ko) 2017-07-05
FI4268843T3 (fi) 2025-11-14
ES2756275T3 (es) 2020-04-27
CL2017001135A1 (es) 2017-12-15
AU2015342882A1 (en) 2017-05-18
ZA201702985B (en) 2019-10-30
JP6594438B2 (ja) 2019-10-23
DK3215530T3 (da) 2019-11-25
MX385206B (es) 2025-03-14
HUE046181T2 (hu) 2020-02-28
US20190194312A1 (en) 2019-06-27
JP2017535285A (ja) 2017-11-30
KR20240023450A (ko) 2024-02-21
EP4268843B1 (en) 2025-09-03
CR20170231A (es) 2017-09-25
MX2021008663A (es) 2021-08-19
LT4268843T (lt) 2025-11-25
BR112017008672A2 (pt) 2018-03-20
EP4268843A3 (en) 2023-12-27
ES2756275T9 (es) 2020-10-29
RS59805B1 (sr) 2020-02-28
IL251858A0 (en) 2017-06-29
PH12017500809B1 (en) 2023-09-20
SA517381458B1 (ar) 2020-07-09
SG10202103420PA (en) 2021-05-28
MY185114A (en) 2021-04-30
SG11201703574VA (en) 2017-05-30
US20220169719A1 (en) 2022-06-02
UA122673C2 (uk) 2020-12-28
CN107249631A (zh) 2017-10-13
WO2016073890A1 (en) 2016-05-12
EP3215530B9 (en) 2020-09-09
CN107249631B (zh) 2021-11-23
EA201791005A1 (ru) 2017-09-29
EP3215530A1 (en) 2017-09-13
MX2017005992A (es) 2017-09-15
PL3215530T3 (pl) 2020-05-18
DK4268843T3 (da) 2025-11-10
CA2965689C (en) 2022-03-22
EP4268843A2 (en) 2023-11-01
HRP20251312T1 (hr) 2025-12-05
HK1244008A1 (en) 2018-07-27
CA2965689A1 (en) 2016-05-12
PT3215530T (pt) 2019-11-21
IL251858B (en) 2022-09-01
KR102636726B1 (ko) 2024-02-13
EP3215530B1 (en) 2019-08-21
RS67353B1 (sr) 2025-11-28
NZ731090A (en) 2024-03-22

Similar Documents

Publication Publication Date Title
IL250583A0 (en) Anti-tigit antibodies
IL252004A0 (en) Ether-substituted antibody
SG11201703403TA (en) Anti-tim-3 antibodies
SG11201703346PA (en) Anti-tim-3 antibodies
SG10201913864RA (en) Anti-LAG-3 Antibodies
IL252422B (en) Effector-deficient anti-cd32a antibodies
ZA201702985B (en) Improved il-6 antibodies
GB201508180D0 (en) Antibodies
GB201410520D0 (en) Antibody
ZA201604640B (en) Novel anti-netrin-1 antibody
IL250374B (en) Antibodies against ceramide
IL248220A0 (en) Anti- nme antibody
SG11201700922YA (en) Anti-orai1 antibody
SI3628731T1 (sl) Novo protitelo proti presepsinu
GB201419089D0 (en) Anti-TIM-3 antibodies
GB201419092D0 (en) Anti-TIM-3 antibodies
GB201417614D0 (en) Antibodies
GB201414270D0 (en) Antibodies
GB201405775D0 (en) Antibodies
GB201401200D0 (en) Antibodies
GB201508437D0 (en) Antibodies
GB201508444D0 (en) Antibodies
GB201507541D0 (en) Antibodies
GB201502591D0 (en) Antibodies
GB201418776D0 (en) Antibody